pegylated interferon lambda-1a peg-ifn-lambda 1 (Bristol Myers)
90
Structured Review
Bristol Myers
pegylated interferon lambda-1a peg-ifn-lambda 1
Pegylated Interferon Lambda 1a Peg Ifn Lambda 1, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pegylated+lambda-1a+(lambda)/peg+interferon+lambda/pmc03411209-38-13-19
Average 90 stars, based on 1 article reviews
Pegylated Interferon Lambda 1a Peg Ifn Lambda 1, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pegylated+lambda-1a+(lambda)/peg+interferon+lambda/pmc03411209-38-13-19
Average 90 stars, based on 1 article reviews
pegylated interferon lambda-1a peg-ifn-lambda 1 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Interferon Lambda: The Next Frontier in Antiviral Therapy? Article Snippet: On 20 April 2016, the clinical-stage biopharmaceutical company Eiger Biopharmaceuticals, announced the acquisition of worldwide rights to Article Title: Liquid protein formulations containing 4-ethyl-4-methylmorpholinium methylcarbonate (EMMC) Article Snippet: Other late-stage protein therapeutics which can be formulated with viscosity-lowering ionic liquids include CM-AT from CureMark LLC; NN7999, NN7088, Liraglutide (NN8022), NN9211, Semaglutide (NN9535) from Novo Nordisk; AMG 386, Filgrastim from Amgen; CSL-654, Factor VIII from CSL Behring; LA-EP2006 (pegfilgrastim biosimilar) from Novartis AG; Multikine (leukocyte interleukin) from CEL-SCI Corporation; LY2605541, Teriparatide (recombinant PTH 1-34) from Eli Lilly; NU-100 from Nuron Biotech, Inc.; Calaspargase Pegol from Sigma-Tau Pharmaceuticals, Inc.; ADI-PEG-20 from Polaris Pharmaceuticals, Inc.; BMN-110, BMN-702 from BioMarin; NGR-TNF from Molmed S.p.A.; recombinant human C1 esterase inhibitor from Pharming Group/Santarus Inc.; Somatropin biosimilar from LG Life Sciences LTD; Natpara from NPS Pharmaceuticals, Inc.; ART123 from Asahi Kasei Corporation; BAX-111 from Baxter; OBI-1 from Inspiration Biopharmaceuticals; Wilate from Octapharma AG; Talactoferrin alfa from Agennix AG; Desmoteplase from Lundbeck; Cinryze from Shire; RG7421 and Roche and Exelixis, Inc.; Midostaurin (PKC412) from Novartis AG; Damoctocog alfa pegol, BAY 86-6150, BAY 94-9027 from Bayer AG; Peginterferon lambda-1a, Article Title: Interferon Regulatory Factor 6 Determines Intestinal Epithelial Cell Development and Immunity Article Snippet: Adult mice were used at 7-10 weeks of age and injected intraperitoneally with 3 μg Article Title: Interferon regulatory factor 6 (IRF6) determines intestinal epithelial cell development and immunity. Article Snippet: Adult mice were used at 7–10 weeks of age and injected intraperitoneally with 3 μg Article Title: Potential of Interferon Lambda as an Inhibitor of SARS-CoV-2 Article Snippet: ZymoGenetics and Article Title: Treatment of chronic hepatitis D with peginterferon lambda—the phase 2 LIMT-1 clinical trial Article Snippet: Other names for Lambda include pegylated interferon lambda (pegIFNλ−1a), PEG-rIL-29, and Injection:Article Title: Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy Article Snippet: Rheumatoid Arthritis (RA) Neonatal-Onset Multisystem Inflammatory Disease (NOMID) , Kineret , Swedish Orphan Biovitrum AB , Nonglycosylated IL-1R antagonist with addition of single methionine residue at the amino terminus , IL-1R1 , ○ Monocytes ○ Macrophages , FDA approval granted after Phase III trials for RA [ 178 ] FDA approval granted after long-term Phase II trials for NOMID [ 179 ] ( {"type":"clinical-trial","attrs":{"text":"NCT00069329","term_id":"NCT00069329"}} NCT00069329 ) , 1.0-mg/kg Anakinra + methotrexate had significantly higher ACR20 response rate (46%) than placebo (19%) [ 178b ] (RA) Improvements occurred in all individual disease symptoms and serum markers of inflammation [ 179b ] (NOMID) , ○ 100mg/day (RA) ○ 1–2mg/kg/day (NOMID) ○ s.c. injection , [ 178 ]. .. Chronic Hepatitis B (HBeAg+ patients) , |